Market Place
Sourcing Support
Ideaya hires Gilead leader to head up commercialization push
19 Nov 2024 //
FIERCE PHARMA
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
18 Nov 2024 //
PR NEWSWIRE
IDEAYA Announces IDE034 Nomination for B7H3/PTK7 ADC
11 Nov 2024 //
PR NEWSWIRE
Biocytogen Announces IDEAYA’s Nomination of IDE034 Bispecific ADC
11 Nov 2024 //
BUSINESSWIRE
IDEAYA Reports Q3 2024 Financial Results and Business Update
04 Nov 2024 //
PR NEWSWIRE
IDEAYA Presents Positive Data for IDE397 in Cancer at EORTC
25 Oct 2024 //
PR NEWSWIRE
IDEAYA Announces IDE397 Phase 1 Results Presentation At EORTC
04 Oct 2024 //
PR NEWSWIRE
IDEAYA Biosciences Names Douglas Snyder as Senior VP, General Counsel
18 Sep 2024 //
PR NEWSWIRE
IDEAYA Biosciences Reports Q2 2024 Results And Business Update
06 Aug 2024 //
PR NEWSWIRE
IDEAYA Announces ADC Program Agreement With Biocytogen
31 Jul 2024 //
PR NEWSWIRE
IDEAYA Closes Public Offering With Full Exercise Of Underwriters` Option
11 Jul 2024 //
PR NEWSWIRE
IDEAYA Announces Public Offering Of Common Stock And Pre-Funded Warrants
09 Jul 2024 //
PR NEWSWIRE
IDEAYA Announces Pricing of Public Offering
09 Jul 2024 //
PR NEWSWIRE
Ideaya Schedules Webcast For IDE397 Phase 2 Data In Cancer On July 8, 2024
05 Jul 2024 //
PR NEWSWIRE
IDEAYA Biosciences Initiates Phase 1 Trial for IDE397 and Trodelvy® Combination
25 Jun 2024 //
PR NEWSWIRE
IDEAYA Biosciences Updates Clinical Program For IDE397 Phase 2 MAT2A Inhibitor
24 Jun 2024 //
PR NEWSWIRE
Ideaya announces results for darovasertib ph 2 IST in neoadjuvant uveal at ASCO
05 Jun 2024 //
PHARMABIZ
IDEAYA`s Darovasertib Uveal Melanoma, Neoadjuvant Data At ASCO
03 Jun 2024 //
PR NEWSWIRE
IDEAYA At June 2024 Investor Relations Events
30 May 2024 //
PR NEWSWIRE
IDEAYA: Daniel Simon Appointed Chief Business Officer
28 May 2024 //
PR NEWSWIRE
Ideaya Darovasertib Uveal Summary: Ph2 Neoadjuvant Asco Oral Presentation
23 May 2024 //
PR NEWSWIRE
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
01 May 2024 //
PR NEWSWIRE
IDEAYA`s Darovasertib Uveal Melanoma Data in ASCO Oral Session
24 Apr 2024 //
PR NEWSWIRE
IDEAYA Selects IDE397 MTAP-Del NSCLC Phase 2 Expansion Dose
22 Apr 2024 //
PR NEWSWIRE
IDEAYA Announces Clinical Collaboration to Evaluate IDE161
12 Mar 2024 //
PR NEWSWIRE
IDEAYA to Participate in Upcoming February 2024 Investor Relations Events
01 Feb 2024 //
PR NEWSWIRE
IDEAYA Bio Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
26 Jan 2024 //
PRESS RELEASE
IDEAYA Announces Participation at the 42nd Annual J.P. Morgan Conference
07 Jan 2024 //
PRESS RELEASE
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023
03 Dec 2023 //
PR NEWSWIRE
IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
PR NEWSWIRE
IDEAYA Biosciences Announces Plans for Investor R&D Day
01 Nov 2023 //
PR NEWSWIRE
IDEAYA Announces Closing of Public Offering to Purchase Additional Shares
27 Oct 2023 //
PRESS RELEASE
IDEAYA Bio Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
27 Oct 2023 //
PRESS RELEASE
IDEAYA Announces Pricing of Public Offering
24 Oct 2023 //
PR NEWSWIRE
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023
17 Oct 2023 //
PR NEWSWIRE
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib
16 Oct 2023 //
PR NEWSWIRE
IDEAYA Announces Development Candidate Nomination of a Werner Helicase Inhibitor
09 Oct 2023 //
PRESS RELEASE
IDEAYA Bio Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06 Oct 2023 //
PRESS RELEASE
IDEAYA Biosciences Receives Fast Track Designation for IDE161
27 Sep 2023 //
PR NEWSWIRE
IDEAYA Announces Phase 1 Expansion for First-in-Class PARG Inhibitor IDE161
11 Sep 2023 //
PR NEWSWIRE
IDEAYA Biosciences Announces Clearance of IND Application for GSK101 (IDE705)
21 Aug 2023 //
PR NEWSWIRE
IDEAYA Announces First-Patient-In for Phase 2 Evaluating Darovasertib
16 Aug 2023 //
PRESS RELEASE
IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
PRESS RELEASE
IDEAYA and Amgen Achieve First-Patient-In for Evaluation of IDE397 and AMG 193
02 Aug 2023 //
PRESS RELEASE
IDEAYA Bio to Participate in Upcoming August 2023 Investor Relations Event
01 Aug 2023 //
PRESS RELEASE
IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1
22 Jun 2023 //
PRESS RELEASE
IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose
12 Jun 2023 //
PR NEWSWIRE
IDEAYA Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
26 May 2023 //
PRESS RELEASE
IDEAYA Announces IND Clearance Enabling Ph 1/2 Trial for Combination of IDE397
22 May 2023 //
PR NEWSWIRE
IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer
16 May 2023 //
PRESS RELEASE
IDEAYA Biosciences, Inc. Reports1Q 2023 FYR and Provides Business Update
09 May 2023 //
PR NEWSWIRE
IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event
01 May 2023 //
PRESS RELEASE
IDEAYA Announces Proposed Public Offering of Common Stock
24 Apr 2023 //
PR NEWSWIRE
Ideaya begins patient dosing in phase 1 trial of IDE161
20 Apr 2023 //
PHARMABIZ
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161
19 Apr 2023 //
PR NEWSWIRE
IDEAYA Announces Presentations for Programs IDE397, IDE161 and Werner Helicase
14 Mar 2023 //
PR NEWSWIRE
IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant
23 Jan 2023 //
PRESS RELEASE
IDEAYA Announces IND Clearance by FDA enabling PI Initiation for IDE161
09 Jan 2023 //
PRESS RELEASE
IDEAYA to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
PRESS RELEASE
IDEAYA Announces Submission of IND Application to the U.S. FDA for IDE161
12 Dec 2022 //
PRNEWSWIRE
